These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18285666)

  • 1. Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan.
    Yamada MF; Fujiwara T; Ishikawa I; Kohata K; Katoh C; Miyamura K; Harigae H
    Tohoku J Exp Med; 2008 Feb; 214(2):97-104. PubMed ID: 18285666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
    Gabert J; Beillard E; van der Velden VH; Bi W; Grimwade D; Pallisgaard N; Barbany G; Cazzaniga G; Cayuela JM; Cavé H; Pane F; Aerts JL; De Micheli D; Thirion X; Pradel V; González M; Viehmann S; Malec M; Saglio G; van Dongen JJ
    Leukemia; 2003 Dec; 17(12):2318-57. PubMed ID: 14562125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.
    van Dongen JJ; Macintyre EA; Gabert JA; Delabesse E; Rossi V; Saglio G; Gottardi E; Rambaldi A; Dotti G; Griesinger F; Parreira A; Gameiro P; Diáz MG; Malec M; Langerak AW; San Miguel JF; Biondi A
    Leukemia; 1999 Dec; 13(12):1901-28. PubMed ID: 10602411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
    Beillard E; Pallisgaard N; van der Velden VH; Bi W; Dee R; van der Schoot E; Delabesse E; Macintyre E; Gottardi E; Saglio G; Watzinger F; Lion T; van Dongen JJ; Hokland P; Gabert J
    Leukemia; 2003 Dec; 17(12):2474-86. PubMed ID: 14562124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol.
    Prezeau N; Silvy M; Gabert J; Picard C
    Leuk Res; 2006 May; 30(5):569-74. PubMed ID: 16209886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative detection of AML1-ETO rearrangement by real-time RT-PCR using fluorescently labeled probes.
    Barragán E; Bolufer P; Moreno I; Martín G; Nomdedeu J; Brunet S; Fernández P; Rivas C; Sanz MA
    Leuk Lymphoma; 2001 Aug; 42(4):747-56. PubMed ID: 11697505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of aml-1/eto fusion gene in patients with acute myeloid leukemia by real-time quantitative RT-PCR].
    Jiang YM; Yuan H; Liu XY; Wang B; Li SJ; Wang N
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):17-22. PubMed ID: 19236739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
    Müller MC; Hördt T; Paschka P; Merx K; La Rosée P; Hehlmann R; Hochhaus A
    Acta Haematol; 2004; 112(1-2):30-3. PubMed ID: 15179002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
    Ross DM; Watkins DB; Hughes TP; Branford S
    Clin Chem; 2008 Sep; 54(9):1568-71. PubMed ID: 18641042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
    Tamaki H; Mishima M; Kawakami M; Tsuboi A; Kim EH; Hosen N; Ikegame K; Murakami M; Fujioka T; Masuda T; Taniguchi Y; Nishida S; Osumi K; Soma T; Oji Y; Oka Y; Kawase I; Sugiyama H; Ogawa H
    Int J Hematol; 2003 Nov; 78(4):349-56. PubMed ID: 14686494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Le H; Ruan GR; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jul; 28(7):433-7. PubMed ID: 18072623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
    Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
    Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
    van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
    Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
    Sacha T; Zawada M; Czekalska S; Florek I; Mueller M; Gniot M; Jaźwiec B; Kyrcz-Krzemień S; Leszczyńska A; Lewandowski K; Matiakowska K; Solarska I; Stokłosa T; Skotnicki AB
    Przegl Lek; 2010; 67(7):454-9. PubMed ID: 21387754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time quantitative reverse transcriptase polymerase chain reaction.
    Fan H; Robetorye RS
    Methods Mol Biol; 2010; 630():199-213. PubMed ID: 20300999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
    Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
    Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
    Goh HG; Lin M; Fukushima T; Saglio G; Kim D; Choi SY; Kim SH; Lee J; Lee YS; Oh SM; Kim DW
    Leuk Lymphoma; 2011 May; 52(5):896-904. PubMed ID: 21338281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].
    Qin YZ; Ruan GR; Li JL; Fu JY; Chang Y; Wang H; Li LD; Liu YR; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):649-52. PubMed ID: 16620548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.